ChristopherEingWeeMD(He/Him)

Oncology • Cleveland, OH

Genitourinary Oncology

Physician

Join to view full profile

Dr. Wee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wee's full profile

Already have an account?

Office
9500 Euclid Ave Ca60
Cleveland, OH 44195
Phone+1 216-444-4730

Fax+1 216-636-9286

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2018 - 2021
Cleveland Clinic FoundationChief Residency, Internal Medicine, 2017 - 2018
Cleveland Clinic FoundationResidency, Internal Medicine, 2014 - 2017
Wayne State University School of MedicineClass of 2014

Certifications & Licensure

IN State Medical License 2024 - 2025
KY State Medical License 2024 - 2025
OH State Medical License 2016 - 2025
PA State Medical License 2024 - 2024
MN State Medical License 2018 - 2022
WI State Medical License 2019 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
Moshe C Ornstein, Laeth George, Wei Wei, C Marcela Diaz-Montero, Pat Rayman
Clinical Genitourinary Cancer. 2024-12-01
3 citations
Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
Shilpa Gupta, Alexander Andreev-Drakhlin, Otto Fajardo, Marcella Fassò, Jorge A Garcia
Journal of the National Cancer Institute. 2024-04-05
3 citations
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation D...
Amanda Nizam, Ryan K Rader, Alice Tzeng, Wei Wei, Iris Yeong-Fung Sheng
Clinical Genitourinary Cancer. 2024-04-01

Abstracts/Posters

WhatÍs in a Name? a Gender-Based Analysis of Speaker Introductions at the American Society of Hematology Annual Meeting
Christopher E. Wee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019